spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  opioid use disorder 

 HSMN NewsFeed - 29 Oct 2024
Protega Pharmaceuticals Receives FDA Approval for ROXYBOND(TM) (oxycodone hydrochloride) Immediate-Release 10 mg Tablet with Abuse-Deterrent Technology for Management of Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Oct 2020
Titan Pharmaceuticals Provides a Strategic & Corporate Update
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jul 2020
Orexo Launches Deprexis(R) and Vorvida(R) in the US and Provides Updated Financial Guidance
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 11 May 2020
Orexo Acquires Exclusive US Rights to Commercialize deprexis(R), A World-leading Digital Therapy to Help Patients Manage the Symptoms of Depression
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Dec 2019
Orexo Appoints Dennis Urbaniak as Executive Vice President Digital Health
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jun 2019
Braeburn Announces Publication of Phase 3 Study Results Showing Long-term Safety and Effectiveness of BRIXADI(TM) (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Biopharmaceuticals
 HSMN NewsFeed - 11 Feb 2019
Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare
Biopharmaceuticals Licensing
 HSMN NewsFeed - 23 Nov 2018
Indivior Announces Health Canada Approval of SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection for Patients with Moderate to Severe Opioid Use Disorder
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 Oct 2018
Titan Strengthens Executive Leadership Team with Appointment of Chief Commercial Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 21 Sep 2018
CHMP Recommends Approval of Buvidal(R) (CAM2038) for the Treatment of Opioid Dependence
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Aug 2018
US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA(TM) (lofexidine) 0.18 Mg Tablets
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 26 Jun 2018
Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA(TM) (lofexidine)
Biopharmaceuticals Distribution
 HSMN NewsFeed - 25 May 2018
Indivior Announces Regulatory Submission to Australia's Therapeutic Goods Administration (TGA) for SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection for the Treatment of Opioid Dependence
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 1 Mar 2018
SUBLOCADE(TM) (Buprenorphine Extended-Release) is Now Available as First and Only Monthly Injectable Buprenorphine in the U.S. to Treat Patients with Moderate to Severe Opioid Use Disorder
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 14 Nov 2017
Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA advisory about deadly risks associated with Kratom
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 May 2017
Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038
Biopharmaceuticals
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.